Comparison · Research scaffold vs. consumer product~5 min readUpdated 12 May 2026

Pseudoindoxyl vs 7-Hydroxymitragynine

Q: Is pseudoindoxyl mitragynine in any kratom or 7-OH products?

No. Mitragynine pseudoindoxyl does not occur naturally in kratom leaf at pharmacologically meaningful concentrations, and it is not a commercially manufactured product. If you encounter a product claiming to contain pseudoindoxyl, that product is either mislabelled (the manufacturer doesn't know what's in it), fraudulently marketed (they're using the name to imply novelty), or actually contains something else entirely. None of those scenarios are safe.

Q: Is pseudoindoxyl safer than 7-OH?

In rodent models, pseudoindoxyl produced analgesia with less respiratory depression, less constipation, and less tolerance buildup than classical opioids — a profile attributed to its combination of mu-agonism, delta-antagonism, and the absence of β-arrestin-2 recruitment (Váradi 2016). But this is preclinical data only. There are no human studies, no safety profiles, no dose-finding data, and no way to verify what's in a product that claims to contain it. 'Potentially safer in rats' is not evidence you can dose yourself with.

Q: Why does 'biased agonism' matter?

A biased opioid agonist preferentially activates G-protein signalling (associated with pain relief) over β-arrestin-2 recruitment (historically linked to respiratory depression and constipation). Pseudoindoxyl was one of the early scaffolds that excited researchers because it showed this bias cleanly. But the biased-agonism hypothesis has come under scrutiny — oliceridine (TRV130), a G-protein-biased opioid, still caused respiratory depression in clinical trials. The concept is pharmacologically interesting but should not be treated as a safety guarantee.

If you've seen 'pseudoindoxyl' on a product label or in a Reddit thread, this page is for you. It's a research chemical — not a kratom product, not a 7-OH alternative, and not something you should be consuming.

What mitragynine pseudoindoxyl actually is

Mitragynine pseudoindoxyl is a structural rearrangement of the indole ring system of mitragynine. It was first characterised as part of a Columbia University medicinal-chemistry programme exploring kratom alkaloid scaffolds for biased opioid agonism (Váradi 2016). In rodent models, the pseudoindoxyl produced morphine-like analgesia with markedly less respiratory depression, less constipation, and reduced tolerance and dependence — a profile attributed to its combination of mu-agonism, delta-antagonism, and the absence of β-arrestin-2 recruitment.

That’s the good news. The caveat: this is preclinical data only. The compound has never been given to a human in a controlled setting. There are no human dose-finding studies, no safety profiles, no pharmacokinetic data, and no way to verify what’s actually in a product that claims to contain it. It is a tool compound for researchers, not a tool compound for consumers.

Table 01 · Pseudoindoxyl vs. 7-OH07 factors

Factor	Pseudoindoxyl	7-Hydroxymitragynine
What it is	A lab-made structural rearrangement of mitragynine	A kratom alkaloid sold in consumer products
Found in kratom leaf?	No — not at pharmacologically meaningful levels	Trace (<0.02%); concentrated to ~98% in commercial products
How it's made	Indole ring rearrangement in a chemistry lab	CYP3A4 oxidation in your liver, or semi-synthetic manufacturing
Receptor profile	Mu agonist + delta antagonist; no β-arrestin-2	Partial mu agonist; reduced β-arrestin-2 recruitment
Preclinical promise	Analgesia with less respiratory depression in rodents	Analgesia confirmed; respiratory margin debated
Human data	None. Zero. Not a single published study.	No controlled trials; extensive observational data
Can you buy it?	No legitimate source — any product claiming it is a red flag	Widely sold as tablets, shots, gummies, powder

The biased-agonism hype — and why it hasn’t delivered (yet)

The excitement around pseudoindoxyl comes from one idea: that biased mu-opioid agonism — preferentially activating G-protein signalling over β-arrestin-2 — could deliver analgesia without the respiratory depression, constipation, and tolerance that make classical opioids dangerous (Váradi 2016; Kruegel 2016).

The hypothesis is pharmacologically interesting. It has also been tempered: oliceridine (TRV130), a G-protein-biased opioid that made it all the way to FDA approval (marketed as Olinvyk), still caused respiratory depression in clinical trials. Biased agonism may reduce some side effects; it does not eliminate them. Pseudoindoxyl remains a starting point for analogue synthesis — a lead compound, not a validated drug.

If you see “pseudoindoxyl” on a product label

This is a red flag, not a selling point. The compound is not commercially manufactured for human consumption. It does not occur naturally in kratom leaf at any meaningful concentration. A product claiming to contain it is in one of three categories:

Mislabelled.The manufacturer is using a scientific-sounding name they don’t understand. You don’t know what’s actually in the product.
Fraudulently marketed.The name is used to imply novelty, purity, or research backing that doesn’t exist for the consumer product.
Actually a research chemical.If it genuinely contains pseudoindoxyl, it was sourced from a research-supply vendor, has no human safety data, and carries risks that haven’t been characterised in any species larger than a rat.

In all three cases: do not consume it. If you’re looking for legitimate 7-OH products from brands with lab-tested formulations, the brand directory and product guide are the right starting points.

Pseudoindoxyl is not an alternative to 7-OH. It is a chemistry paper that has not been tested in humans. Treating it as a consumer product is not cautious experimentation — it’s uninformed risk.

Common questions

03 answers

01Is pseudoindoxyl mitragynine in any kratom or 7-OH products?

No. Mitragynine pseudoindoxyl does not occur naturally in kratom leaf at pharmacologically meaningful concentrations, and it is not a commercially manufactured product. If you encounter a product claiming to contain pseudoindoxyl, that product is either mislabelled (the manufacturer doesn't know what's in it), fraudulently marketed (they're using the name to imply novelty), or actually contains something else entirely. None of those scenarios are safe.

02Is pseudoindoxyl safer than 7-OH?

In rodent models, pseudoindoxyl produced analgesia with less respiratory depression, less constipation, and less tolerance buildup than classical opioids — a profile attributed to its combination of mu-agonism, delta-antagonism, and the absence of β-arrestin-2 recruitment (Váradi 2016). But this is preclinical data only. There are no human studies, no safety profiles, no dose-finding data, and no way to verify what's in a product that claims to contain it. 'Potentially safer in rats' is not evidence you can dose yourself with.

03Why does 'biased agonism' matter?

A biased opioid agonist preferentially activates G-protein signalling (associated with pain relief) over β-arrestin-2 recruitment (historically linked to respiratory depression and constipation). Pseudoindoxyl was one of the early scaffolds that excited researchers because it showed this bias cleanly. But the biased-agonism hypothesis has come under scrutiny — oliceridine (TRV130), a G-protein-biased opioid, still caused respiratory depression in clinical trials. The concept is pharmacologically interesting but should not be treated as a safety guarantee.